Protheon Inc

Menu

About Us

About Us

Pioneering Next-Generation Protein Platforms for Global Health Redefining Biopharma with Advanced Protein Expression and Scalable Solutions
Get Started
Get Started

Who We Are

Change doesn’t come easy—but with bold vision, deep science, and relentless innovation, it’s possible.

Founded by scientists driven to reshape what’s possible in therapeutic protein production, Protheon emerged from years of intense R&D. Our proprietary protein expression system sets a new standard in speed, scalability, and performance—designed to serve both human and animal health on a global scale.

Meet Our Core Team

Dr Shahrzad Ezzatpour

Dr Shahrzad Ezzatpour

PhD

PHD

Biography

Biography

Dr Mohammad Davachi

Dr Mohammad Davachi

PhD

PHD

Biography

Biography

Meet Our Advisory Team

Dr Roddy O'Connor

Roddy O'Connor, Ph.D.

Advisor

Advisor

Linkedin

Linkedin

Prof. Hector Aguilar-Carreno

Hector Aguilar-Carreno Ph.D.

Advisor

Advisor

Linkedin

Linkedin

Potent, precise, next-generation biologics. Engineered for global impact.

Transforming vaccines, antibodies, and therapeutics.

Explore Our Platform
Explore Our Platform

Reshaping health through science and scalable solutions.

Partner With Us
Partner With Us
Scroll to Top

Shahrzad Ezzatpour, PhD

Linkedin X-twitter

PHD-trained microbiologist and immunologist with a Doctor of Veterinary Medicine (DVM), offering integrated expertise in virology, immunology, and comparative medicine. Specialized in the development and execution of in vitro and in vivo models to evaluate vaccine immunogenicity, antiviral efficacy, and pharmacokinetics. Extensive experience working in BSL-3 and ABSL-3 environments with pathogens, including SARS-CoV-2, MERS-CoV, Avian Influenza (H5N1), and other pseudotyped viruses such as Nipah, Hendra, and Ebola. Technical proficiencies include reverse genetics, multicolor flow cytometry, pseudotyped virus systems, and immune profiling.


Contributed to high-impact research programs at globally recognized institutions such as Cornell University with a focus on translational virology, vaccine and therapeutic development, and zoonotic disease modeling. Demonstrated leadership in high-containment laboratory operations, preclinical study design, and regulatory protocol development. Current research at Cornell University centers on multivalent and pseudotyped vaccine platforms and broad-spectrum antiviral strategies targeting emerging viral threats, with emphasis on cross-species viral immunopathogenesis and translational immunoengineering. Research vision is grounded in advancing globally relevant solutions for the development of next-generation vaccines and antiviral therapeutics. Our integrated tech stack is designed to accelerate discovery and delivery—meeting global demand for high-performance biopharmaceuticals that serve both human and animal health.

Dr Mohammad Davachi, PhD

Linkedin X-twitter
Experienced research leader with over 15 years of expertise in biodegradable polymer synthesis, nanocomposite engineering, and biomedical materials development. Specialized in the design, processing, and characterization of multifunctional polymer systems, including triblock copolymers, nano-biocomposites, and drug-loaded microparticles for medical, pharmaceutical, and environmental applications.  

Held academic and research positions in both Iran and the United States, with a focus on tissue engineering scaffolds, sutures, and micro/nano-encapsulation platforms. Demonstrated leadership in polymer process development from bench to pilot scale, with extensive experience in polymer synthesis and processing as well as microfluidics. Currently serving as Assistant Professor at Texas A&M International University, leading federally and industrially funded research on bioresorbable nanocomposites for surgical and regenerative medicine.
Close